Biotech IV Monitor

NBIX — Neurocrine Biosciences Inc.

$15.8B market cap · 8 upcoming readouts tracked

Clinical trial readout dates for Neurocrine Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.

Next readoutFebruary 2027in ~3 months
Upcoming readouts85 Phase 3
Market cap$15.8B
Cash & investments$790Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 2 NBI-1065890
Tardive Dyskinesia · NCT07365462
February 2027
Recruiting
Phase 3 NBI-1065845
Major Depressive Disorder · NCT06963021
July 2027
Recruiting
Phase 3 NBI-1065845
Major Depressive Disorder · NCT06786624
July 2027
Recruiting
Phase 3 NBI-1065845
Major Depressive Disorder · NCT06911112
July 2027
Recruiting
Phase 2 NBI-1117570
Schizophrenia · NCT07288333
August 2027
Recruiting
Phase 3 NBI-1117568
Schizophrenia · NCT06963034
October 2027
Recruiting
Phase 3 NBI-1117568
Schizophrenia · NCT07105098
November 2027
Recruiting
Phase 2 NBI-1117568
Bipolar I Disorder; Mania · NCT07288320
February 2028
Recruiting

Cash position

Neurocrine Biosciences Inc. reported $790M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). It reported net income of $206M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-02

Companies working on similar indications

Discussion

No messages yet. If you follow NBIX, you can start the conversation.
Track NBIX in real time
See live implied volatility for NBIX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NBIX
Contact — questions or corrections about NBIX: dukeupt@gmail.com